Funds › Kalehua Capital Management LLC
Kalehua Capital Management LLC
13F for Q3 2026, filed Nov 13, 2026. 22 positions worth $132.4M.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Kalehua Capital Management LLC in the latest 13F quarter?
Using 13F.ai, how has Kalehua Capital Management LLC's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Kalehua Capital Management LLC's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q3 2026
Largest first. Common shares only.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | MANE Veradermics, Incorporated | 145,695 | $17.7M | 13.3% | -50.0% | 13F ↗ |
| 2 | Ea Series Trust Alpha Arch 1-3 | 148,471 | $17.6M | 13.3% | -34.4% | 13F ↗ |
| 3 | KRSA Korsana Biosciences, Inc. | 442,653 | $14.2M | 10.7% | New | 13F ↗ |
| 4 | XFOR X4 Pharmaceuticals, Inc. | 3.72M | $10.8M | 8.2% | -50.0% | 13F ↗ |
| 5 | ACRS Aclaris Therapeutics, Inc. | 1.83M | $9.6M | 7.3% | -50.0% | 13F ↗ |
| 6 | SRZN Surrozen, Inc. | 286,092 | $9.2M | 7.0% | -62.9% | 13F ↗ |
| 7 | IKT Inhibikase Therapeutics, Inc. | 3.82M | $7.9M | 5.9% | -50.0% | 13F ↗ |
| 8 | SEPN Septerna, Inc. | 194,544 | $7.6M | 5.7% | -50.0% | 13F ↗ |
| 9 | Betterlife Pharma Inc | 27.71M | $6.7M | 5.0% | New | 13F ↗ |
| 10 | OBX Obsidian Therapeutics, Inc. | 416,649 | $5.7M | 4.3% | New | 13F ↗ |
| 11 | IFRX InflaRx N.V. | 2.92M | $5.3M | 4.0% | -49.6% | 13F ↗ |
| 12 | KRRO Korro Bio, Inc. | 473,595 | $4.7M | 3.5% | +16.9% | 13F ↗ |
| 13 | ATTO Attovia Therapeutics, Inc. | 200,000 | $3.4M | 2.6% | New | 13F ↗ |
| 14 | DMRA Damora Therapeutics, Inc. · Comm Stk | 139,000 | $3.0M | 2.2% | New | 13F ↗ |
| 15 | QURE uniQure N.V. | 79,407 | $1.9M | 1.4% | -50.0% | 13F ↗ |
| 16 | GOSS Gossamer Bio, Inc. | 139,366 | $1.7M | 1.2% | New | 13F ↗ |
| 17 | MIST Milestone Pharmaceuticals Inc. | 1.65M | $1.4M | 1.1% | -35.0% | 13F ↗ |
| 18 | LONA LeonaBio, Inc. | 393,701 | $1.4M | 1.1% | -50.0% | 13F ↗ |
| 19 | RNA Atrium Therapeutics, Inc. | 112,652 | $932.8K | 0.7% | New | 13F ↗ |
| 20 | TIL Instil Bio, Inc. | 99,600 | $721.1K | 0.5% | -50.0% | 13F ↗ |
| 21 | ATYR aTyr Pharma, Inc. | 1.83M | $554.3K | 0.4% | -48.8% | 13F ↗ |
| 22 | KZIA Kazia Therapeutics Limited · ADR | 56,013 | $537.4K | 0.4% | New | 13F ↗ |
Changes since Q2 2026
8 new, 1 added to, 13 trimmed, 12 exited, 0 unchanged. By estimated dollars.
New positions (8)
| KRSA Korsana Biosciences, Inc. | 442,653 | New | $14.2M |
| Betterlife Pharma Inc | 27.71M | New | $6.7M |
| OBX Obsidian Therapeutics, Inc. | 416,649 | New | $5.7M |
| ATTO Attovia Therapeutics, Inc. | 200,000 | New | $3.4M |
| DMRA Damora Therapeutics, Inc. · Comm Stk | 139,000 | New | $3.0M |
| GOSS Gossamer Bio, Inc. | 139,366 | New | $1.7M |
| RNA Atrium Therapeutics, Inc. | 112,652 | New | $932.8K |
| KZIA Kazia Therapeutics Limited · ADR | 56,013 | New | $537.4K |
Added to (1)
| Position | Shares | Change | Est. dollars |
|---|---|---|---|
| KRRO Korro Bio, Inc. | 473,595 | +16.9% | $679.4K |
Trimmed (13)
| MANE Veradermics, Incorporated | 145,695 | -50.0% | -$17.7M |
| SRZN Surrozen, Inc. | 286,092 | -62.9% | -$15.6M |
| XFOR X4 Pharmaceuticals, Inc. | 3.72M | -50.0% | -$10.8M |
| ACRS Aclaris Therapeutics, Inc. | 1.83M | -50.0% | -$9.6M |
| Ea Series Trust Alpha Arch 1-3 | 148,471 | -34.4% | -$9.2M |
| IKT Inhibikase Therapeutics, Inc. | 3.82M | -50.0% | -$7.9M |
| SEPN Septerna, Inc. | 194,544 | -50.0% | -$7.6M |
| IFRX InflaRx N.V. | 2.92M | -49.6% | -$5.2M |
| QURE uniQure N.V. | 79,407 | -50.0% | -$1.9M |
| LONA LeonaBio, Inc. | 393,701 | -50.0% | -$1.4M |
Exited (12)
| CMPS COMPASS Pathways Plc · ADR | 1.64M | Exited | -$23.2M |
| SION Sionna Therapeutics, Inc. | 394,144 | Exited | -$17.3M |
| PHVS Pharvaris N.V. | 397,544 | Exited | -$13.7M |
| KPTI Karyopharm Therapeutics Inc. | 1.37M | Exited | -$13.4M |
| Cyclerion Therapeutics Inc | 3.30M | Exited | -$11.2M |
| Damora Therapeutics Inc | 278,000 | Exited | -$7.2M |
| MLTX MoonLake Immunotherapeutics | 351,468 | Exited | -$6.8M |
| TYRA Tyra Biosciences, Inc. | 148,930 | Exited | -$4.8M |
| NVCT Nuvectis Pharma, Inc. | 200,000 | Exited | -$3.7M |
| Gossamer Bio Inc | 22.30M | Exited | -$3.7M |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q3 2026.
Filings
| Filing | ||||||
|---|---|---|---|---|---|---|
| Q3 2026 | Nov 13, 2026 | 13F-HR | 22 | $132.4M | Current | SEC ↗ |
| Q2 2026 | Aug 19, 2026 | 13F-HR/A (new holdings) | 26 | $174.0M | Current | SEC ↗ |
| Q2 2026 | Aug 14, 2026 | 13F-HR | 23 | $139.5M | Current | SEC ↗ |
| Q1 2026 | May 15, 2026 | 13F-HR/A (new holdings) | 25 | $141.3M | Current | SEC ↗ |
| Q1 2026 | May 15, 2026 | 13F-HR | 23 | $118.6M | Current | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | 13F-HR | 19 | $101.1M | Current | SEC ↗ |
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer